Novartis has plans to conduct a Phase III clinical trial to assess canakinumab (Ilaris) for the treatment of patients suffering from Covid-19 pneumonia.
Canakinumab is an interleukin (IL)-1β blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis.
Go deeper with GlobalData
The new Phase III trial, called CAN-COVID, will evaluate the drug’s efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.
